Pricing

  For pricing information, USA customers sign in.
  Outside USA? Please contact your distributor for pricing.

Specifications

A farnesyltransferase inhibitor. Sensitizes human multiple myeloma cell to proteasome inhibition by blocking degradation of bortezomib-induced aggresomes. Also shown to inhibit the growth of myeloid leukemia cell lines and primary leukemia cells by inducing apoptosis and cell-cycle blockage when combined with rapamycin(R124000).
Catalog #	021888
Melting Point	211-213°C (dec.)
Solubility	Chloroform, Methanol
Specific Rotation	+20.9°C (c=0.7, Methanol)
Method for Determining Identity	Proton NMR, (CDCI3) Spectroscopic and Mass Spectrometric Analysis
TLC Conditions	SiO2; Dichloromethane: Methanol=9:1; Visualized with UV and AMCS; Single spot. Rf=0.45.
Important Note	This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
Toxicity and Hazards
	All products should be handled by qualified personnel only, trained in laboratory procedures.
CAS Number	192185-72-1
Molecular Formula	C27H22CI2N4O
Molecular Weight	489.4
Purity	90%
Form	Supplied as an off-white to pale beige solid.
Important Note	This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
Alternate names	6-[(R)-Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-(+)-R 115777; Zarnestra;